# IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers

> **NCT02882789** · PHASE1 · COMPLETED · sponsor: **LigaChem Biosciences, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LCB01-0371
- **DRUG:** LCB01-0371 400mg

## Key facts

- **NCT ID:** NCT02882789
- **Lead sponsor:** LigaChem Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882789, "IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02882789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*